PE20060461A1 - Combinacion de un anticuerpo her2 y gemcitabina para el tratamiento de cancer resistente al platino - Google Patents

Combinacion de un anticuerpo her2 y gemcitabina para el tratamiento de cancer resistente al platino

Info

Publication number
PE20060461A1
PE20060461A1 PE2005000682A PE2005000682A PE20060461A1 PE 20060461 A1 PE20060461 A1 PE 20060461A1 PE 2005000682 A PE2005000682 A PE 2005000682A PE 2005000682 A PE2005000682 A PE 2005000682A PE 20060461 A1 PE20060461 A1 PE 20060461A1
Authority
PE
Peru
Prior art keywords
combination
her2 antibody
gemcitabin
platinum
treatment
Prior art date
Application number
PE2005000682A
Other languages
English (en)
Spanish (es)
Inventor
Stephen M Kelsey
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35432102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060461(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20060461A1 publication Critical patent/PE20060461A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PE2005000682A 2004-06-16 2005-06-15 Combinacion de un anticuerpo her2 y gemcitabina para el tratamiento de cancer resistente al platino PE20060461A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58033304P 2004-06-16 2004-06-16

Publications (1)

Publication Number Publication Date
PE20060461A1 true PE20060461A1 (es) 2006-08-04

Family

ID=35432102

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000682A PE20060461A1 (es) 2004-06-16 2005-06-15 Combinacion de un anticuerpo her2 y gemcitabina para el tratamiento de cancer resistente al platino

Country Status (27)

Country Link
US (2) US20060013819A1 (https=)
EP (1) EP1755671B1 (https=)
JP (3) JP2008503476A (https=)
KR (3) KR20130038407A (https=)
CN (2) CN101014366A (https=)
AR (1) AR049305A1 (https=)
AU (2) AU2005262459B2 (https=)
BR (1) BRPI0511377A (https=)
CA (1) CA2567808C (https=)
DK (1) DK1755671T3 (https=)
ES (1) ES2398689T3 (https=)
GT (1) GT200500155A (https=)
IL (1) IL179401A (https=)
JO (1) JO2794B1 (https=)
MX (1) MXPA06014687A (https=)
MY (1) MY163024A (https=)
NO (1) NO20070243L (https=)
NZ (1) NZ551376A (https=)
PA (1) PA8637101A1 (https=)
PE (1) PE20060461A1 (https=)
PL (1) PL1755671T3 (https=)
RU (1) RU2403065C2 (https=)
SI (1) SI1755671T1 (https=)
SV (1) SV2006002143A (https=)
TW (1) TWI375564B (https=)
WO (1) WO2006007398A1 (https=)
ZA (1) ZA200610132B (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
KR20130056201A (ko) * 2000-05-19 2013-05-29 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
KR20140032004A (ko) 2004-07-22 2014-03-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008523073A (ja) * 2004-12-07 2008-07-03 ジェネンテック・インコーポレーテッド Ｈｅｒ阻害剤を用いた治療のための患者の選択
CA2592177A1 (en) * 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
SI1853250T1 (sl) 2005-02-18 2012-01-31 Abraxis Bioscience Llc Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
EP1850874B1 (en) * 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US20080045589A1 (en) * 2006-05-26 2008-02-21 Susan Kelley Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
JP2009539836A (ja) * 2006-06-05 2009-11-19 ジェネンテック・インコーポレーテッド ＥＧＦまたはＴＧＦ−αのレベルの上昇が生じている癌患者の生存の延長
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
EP3470071A1 (en) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
MX2009008981A (es) * 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
NZ617520A (en) 2008-02-25 2015-05-29 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
JP2010006705A (ja) * 2008-06-13 2010-01-14 Atlas Antibodies Ab Ｈｅｒ２サブセット
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
AU2009308707A1 (en) * 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
BRPI1014449A2 (pt) 2009-04-07 2017-06-27 Roche Glycart Ag anticorpos biespecíficos anti-erbb-2/ anti-c-met.
AU2010273319B2 (en) 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
US10143652B2 (en) * 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
CA2781529C (en) * 2009-09-23 2017-10-24 Indu Javeri Methods for the preparation of liposomes comprising docetaxel
EP2507381A4 (en) * 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
ES2594893T3 (es) * 2009-12-16 2016-12-23 Abbvie Biotherapeutics Inc. Anticuerpos anti HER2 y sus usos
KR102104197B1 (ko) * 2010-02-23 2020-04-24 제넨테크, 인크. 난소암의 치료를 위한 항혈관신생 요법
NZ717490A (en) 2010-03-29 2017-12-22 Abraxis Bioscience Llc Methods of treating cancer
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
BR112012030909A2 (pt) 2010-06-04 2020-08-18 Abraxis Bioscience, Llc métodos de tratamento de câncer pancreático
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
JP2014513692A (ja) * 2011-05-09 2014-06-05 ユニバーシティ オブ バージニア パテント ファウンデーション 癌を治療するための組成物及び方法
JP6186575B2 (ja) * 2011-09-02 2017-08-30 ダイアテック ホールディングス， インコーポレイテッドＤｉａＴｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｉｎｃ． 治療有効性を判定するためのシグナル経路タンパク質のプロファイリング
WO2013055874A2 (en) 2011-10-14 2013-04-18 Genentech, Inc. Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
WO2013108869A1 (ja) * 2012-01-20 2013-07-25 国立大学法人岡山大学 がんの治療又は予防剤
WO2013135602A2 (en) 2012-03-13 2013-09-19 F. Hoffmann-La Roche Ag Combination therapy for the treatment of ovarian cancer
NZ629283A (en) * 2012-03-16 2016-04-29 Covagen Ag Novel binding molecules with antitumoral activity
EP2638916A1 (en) * 2012-03-16 2013-09-18 Covagen AG Novel binding molecules with antitumoral activity
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
US20160067182A1 (en) * 2013-04-09 2016-03-10 Merrimack Pharmaceuticals, Inc. Methods and compositions for improving outcomes of liposomal chemotherapy
RU2019115089A (ru) 2013-04-16 2019-06-11 Дженентек, Инк. Варианты пертузумаба и их аналитическая характеристика
WO2014208760A1 (ja) * 2013-06-27 2014-12-31 国立大学法人九州大学 抗がんモノクローナル抗体及びその製造方法
CN104726462A (zh) * 2013-12-20 2015-06-24 北京天广实生物技术股份有限公司 抗her2人源化抗体mil41、其制备方法及用途
JP2017513901A (ja) 2014-04-25 2017-06-01 ジェネンテック， インコーポレイテッド トラスツズマブ−ｍｃｃ−ｄｍ１及びペルツズマブにより早期の乳癌を処置する方法
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
US11406715B2 (en) 2015-05-30 2022-08-09 Genentech, Inc. Methods of treating HER2-positive metastatic breast cancer
US9770462B2 (en) 2015-10-05 2017-09-26 National Cheng Kung University Method of treating ovarian, tubal and peritoneal cancer
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
FI127460B (en) * 2016-01-15 2018-06-29 Targovax Oy Combining adenovirus and chemotherapeutic agents for treating cancer
AU2017355432A1 (en) 2016-11-04 2019-05-16 F. Hoffmann-La Roche Ag Treatment of HER2-positive breast cancer
AU2017387909A1 (en) 2016-12-28 2019-06-27 Genentech, Inc. Treatment of advanced HER2 expressing cancer
SG11201905622VA (en) 2017-01-17 2019-08-27 Genentech Inc Subcutaneous her2 antibody formulations
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
EP3615695A1 (en) 2017-04-24 2020-03-04 Genentech, Inc. Erbb2/her2 mutations in the transmebrane or juxtamembrane domain
RU2738167C1 (ru) * 2020-06-08 2020-12-09 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии" Министерства здравоохранения Российской Федерации Способ определения эффективности химиотерапии препаратами платины при раке яичников III-IV стадии
AU2020456731A1 (en) 2020-06-29 2023-01-05 F. Hoffmann-La Roche Ag Pertuzumab plus trastuzumab fixed dose combination

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5824311A (en) * 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6884418B1 (en) * 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US6287784B1 (en) 1993-11-23 2001-09-11 Genentech, Inc. Kinase receptor activation assay
WO1995014930A1 (en) 1993-11-23 1995-06-01 Genentech, Inc. Kinase receptor activation assay
AU697142B2 (en) 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JP2002507404A (ja) * 1998-03-27 2002-03-12 ジェネンテク・インコーポレイテッド Ａｐｏ−２リガンド−抗ＨＥＲ−２抗体相乗作用
PT1308456E (pt) * 1998-05-06 2007-12-03 Genentech Inc Purificação de anticorpos por cromatografia de permuta iónica
US7041292B1 (en) * 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CA2376596C (en) * 1999-06-25 2009-10-06 Genentech, Inc. Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
IL147017A0 (en) * 1999-06-25 2002-08-14 Genentech Inc TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
TR200200472T2 (tr) * 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
KR20130056201A (ko) * 2000-05-19 2013-05-29 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
JP2004002211A (ja) * 2001-04-27 2004-01-08 Takeda Chem Ind Ltd 癌の予防・治療方法
US20030190689A1 (en) 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
GB0215593D0 (en) * 2002-07-05 2002-08-14 Univ Leeds New anticancer drugs
ES2392525T3 (es) * 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
JP2006516117A (ja) * 2002-11-21 2006-06-22 ジェネンテック・インコーポレーテッド 抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療
JP4969440B2 (ja) * 2004-04-08 2012-07-04 デビッド， ビー． エイガス， 疼痛治療のためのＥｒｂＢアンタゴニスト
KR20120064120A (ko) * 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
EP1755608A1 (en) * 2004-06-03 2007-02-28 F.Hoffmann-La Roche Ag Treatment with gemcitabine and an egfr-inhibitor
KR20140032004A (ko) * 2004-07-22 2014-03-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008523073A (ja) * 2004-12-07 2008-07-03 ジェネンテック・インコーポレーテッド Ｈｅｒ阻害剤を用いた治療のための患者の選択
CA2592177A1 (en) * 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
EP1850874B1 (en) * 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
WO2006096861A2 (en) * 2005-03-08 2006-09-14 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
US9135948B2 (en) 2009-07-03 2015-09-15 Microsoft Technology Licensing, Llc Optical medium with added descriptor to reduce counterfeiting

Also Published As

Publication number Publication date
TW200610538A (en) 2006-04-01
JP2008503476A (ja) 2008-02-07
AU2005262459A1 (en) 2006-01-19
EP1755671A1 (en) 2007-02-28
MXPA06014687A (es) 2007-02-12
KR101517715B1 (ko) 2015-05-04
US20120107391A1 (en) 2012-05-03
JO2794B1 (en) 2014-03-15
CN105194667A (zh) 2015-12-30
BRPI0511377A (pt) 2007-12-04
PA8637101A1 (es) 2006-05-16
ZA200610132B (en) 2009-08-26
WO2006007398A9 (en) 2007-02-01
EP1755671B1 (en) 2012-12-12
RU2007101378A (ru) 2008-07-27
JP2013014611A (ja) 2013-01-24
RU2403065C2 (ru) 2010-11-10
KR20130038407A (ko) 2013-04-17
PL1755671T3 (pl) 2013-05-31
SI1755671T1 (sl) 2013-03-29
GT200500155A (es) 2006-05-15
AR049305A1 (es) 2006-07-12
NO20070243L (no) 2007-01-15
ES2398689T3 (es) 2013-03-21
CA2567808C (en) 2014-03-18
CA2567808A1 (en) 2006-01-19
KR20070029804A (ko) 2007-03-14
MY163024A (en) 2017-07-31
US20060013819A1 (en) 2006-01-19
IL179401A0 (en) 2007-05-15
NZ551376A (en) 2009-11-27
WO2006007398A1 (en) 2006-01-19
AU2011200947A1 (en) 2011-03-24
JP2015157831A (ja) 2015-09-03
IL179401A (en) 2012-12-31
HK1102757A1 (en) 2007-12-07
TWI375564B (en) 2012-11-01
KR20140012197A (ko) 2014-01-29
SV2006002143A (es) 2006-01-26
CN101014366A (zh) 2007-08-08
DK1755671T3 (da) 2013-03-25
AU2005262459B2 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
PE20060461A1 (es) Combinacion de un anticuerpo her2 y gemcitabina para el tratamiento de cancer resistente al platino
AR065589A1 (es) Prediccion de respuesta a un inhibidor her
MX2020001550A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
PE20141381A1 (es) Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer
CL2018000223A1 (es) Combinación de antagonista de pd-1 con un inhibidor de egfr
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
CL2008002130A1 (es) Compuestos derivados de 2-amino-cromen-4-ona; composicion farmaceutica que lo comprende; y uso en el tratamiento de una enfermedad que es aliviada por la inhibicion de la proteina quinasa dependiente de adn (adn-pk), tal como cancer.
MX340724B (es) Terapia anti-angiogenesis para el tratamiento del cancer de mama.
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
PE20142046A1 (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
PE20121555A1 (es) COMBINACION DE UN AGENTE INDUCTOR DE POLIPLOIDIA Y UN INHIBIDOR Bcl-2
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
CL2009000721A1 (es) Combinacion que comprende un anticuerpo aislado anti-igf1r o un fragmento de fijacion de antigeno del mismo en asociacion con leucovorina y 5-fluorouracilo, leucovorina o sunitinib opcionalmente asociado con otro agente quimioterapeutico; y su uso para el tratamiento o prevencion del cancer colorectal.
PE20170242A1 (es) Composiciones de portador-anticuerpo y metodos para realizarlas y utilizarlas
CR10308A (es) Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito
PA8850801A1 (es) Compuestos útiles para inhibir chk1
AR077866A1 (es) Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina
CL2011001256A1 (es) Combinacion farmaceutica que comprende a un anticuerpo que reconoce especificamente a cd38, y ciclofosfamida, donde dicho anticuerpo es capaz de eliminar una celula cd38+ por apoptosis, citotoxicidad mediada por celulas dependiente de anticuerpo (adcc), y citotoxicidad dependiente de complemento (cdc).
MX2019001315A (es) Tratamiento conjunto contra tipos de cancer hematologico.
CU24349B1 (es) Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer
PE20150212A1 (es) Anticuerpos anti-trka con propiedades inhibitorias mejoradas y sus derivados
CL2008001533A1 (es) Formulacion que comprende triazinonas y compuestos o complejos ferricos, utiles para preparar medicamentos para uso veterinario contra la coccidiosis y deficiencias de hierro.
PE20081553A1 (es) Composicion farmaceutica que comprende un anticuerpo monoclonal anti cd6 utilizado en el diagnostico y tratamiento de la artritis reumatoide
CL2011001860A1 (es) Compuestos derivados de indol; procedimiento de preparacion de dichos compuestos; composicion y combinacion farmaceutica; y uso en el tratamiento del cancer.
MX2019015207A (es) Compuestos para tratar el cancer de ovario.

Legal Events

Date Code Title Description
FC Refusal